| Literature DB >> 28485321 |
Wei Du1, Xiao-Ting Wang1, Yun Long1, Da-Wei Liu1.
Abstract
BACKGROUND: Evaluating the hemodynamic status and predicting fluid responsiveness are important in critical ultrasound assessment of shock patients. Transthoracic echocardiography with noninvasive diagnostic parameters allows the assessment of volume responsiveness. This study aimed to assess the hemodynamic changes in the liver and systemic hemodynamic changes during fluid challenge and during passive leg raising (PLR) by measuring hepatic venous flow (HVF) velocity.Entities:
Mesh:
Year: 2017 PMID: 28485321 PMCID: PMC5443027 DOI: 10.4103/0366-6999.205848
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Figure 1The test flow chart of this study. PLR: Passive leg raising; VE: Volume expansion; CO: Cardiac output; HVF: Hepatic venous flow; RV function: Right ventricular function.
Characteristics of patients with shock at baseline (n = 42)
| Characteristics | Values |
|---|---|
| Age (years), mean ± SD | 59 ± 14 |
| Sex (male/female) | 22/20 |
| APACHE II score, mean ± SD | 18 ± 6 |
| Source of infection, | |
| Pneumonia | 12 (29) |
| Bacteremia | 20 (48) |
| Urinary | 2 (5) |
| Abdominal | 7 (17) |
| Unknown | 1 (2) |
| Vasopressors | |
| Norepinephrine, | 42 (100) |
| Norepinephrine dosage (µg·kg−1·min−1), mean ± SD | 0.34 ± 0.11 |
| Dobutamine, | 10 (24) |
| LVEF (%), mean ± SD | 53.0 ± 10.4 |
| Acute respiratory distress syndrome, | 16 (33) |
| Atrial fibrillation, | 13 (31) |
| Spontaneous breathing activity, | 30 (71) |
LVEF: Left ventricular ejection fraction; APACHE II: Acute Physiology and Chronic Health Evaluation II scores; SD: Standard deviation.
Hemodynamic variables of patients with shock between baseline and during PLR
| Variables | Baseline | During PLR | ||
|---|---|---|---|---|
| Heart rate | ||||
| Responders ( | 87.5 ± 18.1 | 86.1 ± 19.2 | −0.132 | 0.893 |
| Nonresponders ( | 81.5 ± 16.4 | 80.5 ± 16.5 | 0.432 | 0.674 |
| Systolic arterial pressure (mmHg) | ||||
| Responders ( | 120.3 ± 17.2 | 127.3 ± 14.4 | −1.597 | 0.133 |
| Nonresponders ( | 118.7 ± 17.1 | 125.3 ± 15.2 | −1.357 | 0.202 |
| Diastolic artery pressure (mmHg) | ||||
| Responders ( | 60.4 ± 9.1 | 63.2 ± 9.5 | −1.317 | 0.212 |
| Nonresponders ( | 62.3 ± 8.4 | 65.2 ± 9.2 | −0.927 | 0.375 |
| Mean arterial pressure (mmHg) | ||||
| Responders ( | 89.1 ± 11.7 | 92.4 ± 9.4 | −1.529 | 0.150 |
| Nonresponders ( | 85.1 ± 10.1 | 91.2 ± 10.3 | −1.414 | 0.183 |
| VTIAo (cm) | ||||
| Responders ( | 18.3 ± 5.5 | 22.3 ± 6.3 | −7.335 | 0.000 |
| Nonresponders ( | 19.1 ± 4.8 | 21.7 ± 5.4 | −0.857 | 0.402 |
| Stroke volume (ml) | ||||
| Responders ( | 57.2 ± 22.8 | 69.2 ± 26.3 | −6.631 | 0.000 |
| Nonresponders ( | 61.3 ± 14.1 | 68.5 ± 15.4 | −1.122 | 0.284 |
| Cardiac output (L/min) | ||||
| Responders ( | 4.7 ± 1.9 | 5.5 ± 1.8 | −5.035 | 0.000 |
| Nonresponders ( | 5.0 ± 1.3 | 5.2 ± 1.5 | −1.091 | 0.244 |
| Middle hepatic vein S-wave (cm/s) | ||||
| Responders ( | 30.1 ± 10.2 | 31.2 ± 12.4 | −0.745 | 0.473 |
| Nonresponders ( | 33.9 ± 12.2 | 37.5 ± 15.3 | −1.802 | 0.090 |
| Middle hepatic vein D-wave | ||||
| Responders ( | 23.3 ± 6.1 | 26.2 ± 6.3 | −2.295 | 0.115 |
| Nonresponders ( | 24.6 ± 9.8 | 26.0 ± 10.7 | −1.345 | 0.302 |
| Middle hepatic vein A-wave (cm/s) | ||||
| Responders ( | 29.3 ± 11.1 | 22.7 ± 6.7 | −0.140 | 0.891 |
| Nonresponders ( | 25.5 ± 5.3 | 24.4 ± 7.2 | −0.695 | 0.529 |
| Middle hepatic vein S/D | ||||
| Responders ( | 1.3 ± 0.3 | 1.1 ± 0.1 | 1.241 | 0.313 |
| Nonresponders ( | 1.3 ± 0.3 | 1.1 ± 0.4 | 1.921 | 0.129 |
All results reported as mean ± SD. VTIAo: Aortic velocity-time integral; SD: Standard deviation; PLR: Passive leg raising.
Hemodynamic variables of patients with shock between baseline and after volume expansion
| Variables | Baseline | After volume expansion | ||
|---|---|---|---|---|
| Heart rate (beats/min) | ||||
| Responders ( | 87.5 ± 18.1 | 84.7 ± 18.2 | 2.473 | 0.029 |
| Nonresponders ( | 81.5 ± 16.4 | 79.8 ± 17.1 | 0.531 | 0.608 |
| Systolic arterial pressure (mmHg) | ||||
| Responders ( | 120.3 ± 17.2 | 126.2 ± 19.8 | −1.943 | 0.076 |
| Nonresponders ( | 118.7 ± 17.1 | 123.2 ± 14.4 | −0.765 | 0.462 |
| Diastolic artery pressure (mmHg) | ||||
| Responders ( | 60.4 ± 9.1 | 61.1 ± 9.3 | −0.361 | 0.721 |
| Nonresponders ( | 62.3 ± 8.4 | 62.3 ± 9.2 | 0.338 | 0.752 |
| Mean arterial pressure (mmHg) | ||||
| Responders ( | 89.1 ± 11.7 | 91.0 ± 12.4 | −1.145 | 0.275 |
| Nonresponders ( | 85.1 ± 10.1 | 86.3 ± 10.2 | −0.095 | 0.924 |
| VTIAo (cm) | ||||
| Responders ( | 18.3 ± 5.5 | 22.8 ± 5.3 | −7.781 | 0.000 |
| Nonresponders ( | 19.1 ± 4.8 | 22.1 ± 5.3 | −1.039 | 0.124 |
| Stroke volume (ml) | ||||
| Responders ( | 57.2 ± 22.8 | 70.1 ± 24.2 | −6.859 | 0.000 |
| Nonresponders ( | 61.3 ± 14.1 | 63.7 ± 15.2 | −0.194 | 0.236 |
| Cardiac output (L/min) | ||||
| Responders ( | 4.7 ± 1.9 | 5.9 ± 2.1 | −8.788 | 0.000 |
| Nonresponders ( | 5.0 ± 1.3 | 5.4 ± 1.4 | −1.025 | 0.244 |
| Middle hepatic vein S wave (cm/s) | ||||
| Responders ( | 30.1 ± 10.2 | 37.1 ± 12.5 | −3.717 | 0.003 |
| Nonresponders ( | 33.9 ± 12.2 | 34.8 ± 15.7 | −0.415 | 0.475 |
| Middle hepatic vein D wave (cm/s) | ||||
| Responders ( | 23.3 ± 6.1 | 25.4 ± 7.1 | −0.984 | 0.355 |
| Nonresponders ( | 24.6 ± 9.8 | 36.8 ± 15.1† | −6.429 | 0.000 |
| Middle hepatic vein A wave (cm/s) | ||||
| Responders ( | 29.3 ± 11.1 | 27.5 ± 4.2 | 0.085 | 0.933 |
| Nonresponders ( | 25.5 ± 5.3 | 25.5 ± 5.5 | 0.009 | 0.994 |
| Middle hepatic vein S/D | ||||
| Responders ( | 1.3 ± 0.3 | 1.5 ± 0.2 | −1.392 | 0.169 |
| Nonresponders ( | 1.3 ± 0.3 | 1.4 ± 0.3 | 1.401 | 0.181 |
| IVC diameter (cm) | ||||
| Responders ( | 1.5 ± 0.4 | 1.7 ± 0.4 | −3.578 | 0.004 |
| Nonresponders ( | 1.7 ± 0.6 | 1.8 ± 0.6 | 0.298 | 0.771 |
| TAPSE (cm) | ||||
| Responders ( | 1.8 ± 0.4 | 1.8 ± 0.4 | 0.589 | 0.547 |
| Nonresponders ( | 2.1 ± 0.3 | 2.1 ± 0.3 | 0.321 | 0.715 |
| RV end-diastolic diameter (cm) | ||||
| Responders ( | 2.7 ± 0.3 | 2.8 ± 0.7 | −0.586 | 0.579 |
| Nonresponders ( | 3.2 ± 0.4* | 3.2 ± 0.5 | 0.296 | 0.772 |
| Tricuspid valve | ||||
| E peak velocity (cm/s) | ||||
| Responders ( | 45.1 ± 14.5 | 53.1 ± 20.6 | 1.950 | 0.077 |
| Nonresponders ( | 51.7 ± 14.9 | 53.2 ± 15.1 | −0.782 | 0.451 |
| A peak velocity (cm/s) | ||||
| Responders ( | 51.5 ± 9.7 | 53.7 ± 12.2 | −0.782 | 0.448 |
| Nonresponders ( | 50.6 ± 10.2 | 49.7 ± 14.3 | −0.724 | 0.486 |
| Sa (cm/s) | ||||
| Responders ( | 11.6 ± 3.3 | 12.2 ± 4.3 | −0.973 | 0.352 |
| Nonresponders ( | 12.7 ± 3.2 | 12.0 ± 3.1 | 1.651 | 0.133 |
| Ea (cm/s) | ||||
| Responders ( | 8.4 ± 4.4 | 9.2 ± 4.2 | −0.696 | 0.501 |
| Nonresponders ( | 10.9 ± 5.2 | 11.2 ± 5.3 | −0.538 | 0.604 |
| Aa (cm/s) | ||||
| Responders ( | 13.9 ± 4.5 | 14.5 ± 4.5 | −0.432 | 0.674 |
| Nonresponders ( | 16.2 ± 5.7 | 16.9 ± 8.5 | −0.390 | 0.714 |
| E/Ea | ||||
| Responders ( | 6.1 ± 2.3 | 6.5 ± 2.7 | −0.292 | 0.771 |
| Nonresponders ( | 5.7 ± 3.2 | 5.4 ± 2.8 | 0.380 | 0.714 |
All results reported as mean ± SD. *P<0.05 comparing responders with nonresponders in baseline; †P<0.05 comparing responders with nonresponders after volume expansion. VTIAo: Aortic velocity-time integral; IVC: Inferior vena cava; TAPSE: Tricuspid annular plane systolic excursion; RV: Right ventricular; Sa: Tricuspid annular systolic velocity at the lateral wall measured by tissue-Doppler pulse wave; Ea: Early diastolic velocity at the lateral wall measured by tissue-Doppler pulse wave; Aa: Late diastolic velocity at the lateral wall measured by tissue-Doppler pulse wave; SD: Standard deviation.
Figure 2ROC curve analysis showing the relationship between CO and ΔMHV D. ΔMHV D was able to accurately detect <15% increase in CO on ROC curve analysis. ΔMHV D >21% was associated with no increase in CO during volume expansion, with a sensitivity of 100%, a specificity of 71%, and an AUC of 0.918. MHV DafterVE >31.4 cm/s was associated with no increase in CO during volume expansion, with a sensitivity of 73%, a specificity of 84%, and an AUC of 0.772. CO: Cardiac output; AUC: Area under the curve; ROC: Receiver operating characteristic; MHV: Middle hepatic venous.
Univariate analyses of middle hepatic vein flow in relation to right ventricular filling
| Ranked variables | IVC diameter | TAPSE | RVEDD | Tricuspid valve | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| E | A | E/A | Sa | Ea | Aa | E/Ea | ||||
| Baseline | ||||||||||
| MHV S | ↑* | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| MHV D | ↑† | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| MHV A | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| MHV S/D | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| Postventricular | ||||||||||
| MHV S | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| MHV D | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| MHV A | ↓ | ↓ | ↓ | ↓ | ↑‡ | ↓ | ↓ | ↓ | ↓ | ↓ |
| MHV S/D | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
↓: Nonsignificant; ↑: Significant; *↑: P = 0.030; †↑: P = 0.035; ‡↑: P = 0.009. MHV: Middle hepatic venous; IVC: Inferior vena cava; TAPSE: Tricuspid annular plane systolic excursion; RVEDD: Right ventricular end-diastolic diameter; Sa: Tricuspid annular systolic velocity at the lateral wall measured by tissue-Doppler pulse wave; Ea: Early diastolic velocity at the lateral wall measured by tissue-Doppler pulse wave; Aa: Late diastolic velocity at the lateral wall measured by tissue-Doppler pulse wave.
Figure 3The hepatic vein waveform obtained in baseline and after volume expansion. (a) The patient who has fluid responsiveness: The S-wave increased with volume expansion. (b) The patient who lack fluid responsiveness: The D-wave increased with volume expansion, and the ΔMHV D, calculated as (38.4 − 17.4)/17.4 × 100% = 121%, far more than 21% as this study shows. MHV: Middle hepatic venous.